MOSCOW, February 5. /TASS/. The results of the first and second stages of clinical trials of the Epivaccorona vaccine will be published by the end of February, the press service of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing informed on Friday.
"The results of preventive effectiveness trials on the outcomes of first and second stages of the Epivaccorona vaccine will be published in February 2021," the message says.
The press service added that the watchdog’s officials had held meetings with participants of clinical trials to discuss whether the period of observation can be decreased from six months to three months. The regulator explained that holding controlled blind randomized clinical trials in the conditions when a number of vaccines became available in Russia for civilian circulation creates certain ethical concerns.
On July, 24, 2020, the Vector State Research Center of Virology and Biotechnology received a Russian health ministry permit for clinical trials of its anti-coronavirus vaccine on volunteers. The first volunteer was inoculated on July 27. The vaccine’s clinical trials were completed on September 30. Russian President Vladimir Putin said on October 14 that the Vector-developed vaccine had received registration. On November 16, the health ministry issued a permit for post-registration trials of the vaccine on volunteers older than 60 and a permit for tests on 3,000 volunteers aged from 18 to 60 was issued on November 18.